



**Telix Pharmaceuticals Limited**  
ACN 616 620 369  
55 Flemington Road  
North Melbourne  
Victoria, 3051  
Australia

## **ASX ANNOUNCEMENT**

### **Andreas Kluge to Retire from Telix Board**

*Melbourne (Australia) – 17 October 2024.* Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Non-Executive Director (NED) and Co-Founder of Telix, Andreas Kluge, will retire from the Company's Board, effective today, 17 October 2024.

Dr. Kluge has been a Director of Telix since the Company's inception in 2017<sup>1</sup>. Following retirement as a NED, Dr. Kluge will be engaged by Telix on a consultancy basis and will continue to provide the Board of Directors strategic advice alongside clinical input into key development programs, reflective of his ongoing importance as a founder of the Company.

Mr. Kevin McCann AO, Chairman, Telix, said, "Andreas has made a significant contribution to the Board. His nuanced understanding of the clinical development and commercialisation process for radiopharmaceuticals has been invaluable as we've advanced our theranostic pipeline. We thank him for his service."

Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer, Telix, said, "When Andreas and I founded Telix we had an ambitious vision to create a global radiopharmaceutical company that would make a difference to the lives of cancer patients. We have made measurable progress toward achieving that goal, and Andreas has been instrumental to this success. I thank him for his hard work and support over the years and I look forward to continuing to work with him in a more innovative capacity."

Dr. Kluge, said. "Telix has achieved many important milestones in recent years and is on the cusp of significant future growth as a more mature and commercially focused organisation. I am proud of what we have achieved since the Company's inception and thank Telix colleagues, fellow Directors and my co-founder Chris, for their support over the years. I look forward to continuing to support the Company as an active shareholder and to continuing my involvement in an advisory manner."

The Board continues to assess the skills and experience needed for strong stewardship and governance and intends to make new appointments in due course.

#### **About Telix Pharmaceuticals Limited**

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit [www.telixpharma.com](http://www.telixpharma.com) for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on [X](#) and [LinkedIn](#).

---

<sup>1</sup> Dr Kluge was appointed Executive Director on 3 January 2017 and transitioned to Non-Executive Director on 2 June 2020.

---

## Telix Investor Relations

Ms. Kyahn Williamson  
Telix Pharmaceuticals Limited  
SVP Investor Relations and Corporate Communications  
Email: [kyahn.williamson@telixpharma.com](mailto:kyahn.williamson@telixpharma.com)

*This announcement has been authorised for release by the Telix Pharmaceuticals Limited Board of Directors.*

### Legal Notices

*You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX) or on our website.*

*The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.*

*This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.*

*©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.*